Why this is trending right now
On November 21, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for Deramiocel (CAP-1002), a cell therapy developed by Capricor Therapeutics for Duchenne cardiomyopathy. The agency's refusal to approve the current application stems from “serious clinical trial data integrity deficiencies” identified during Study HOPE-3, which officials determined rendered the clinical data unreliable and incapable of post hoc remediation.
The last 24 hours: a timeline
Throughout the morning of November 21, the healthcare and investment sectors responded to the regulatory setback. Following the official FDA announcement, Parent Project Muscular Dystrophy released a statement highlighting the "devastating" nature of the decision for the Duchenne community. The FDA specified that its rejection was based on a review concluded by November 20, 2026, which found unauthorized changes to the study’s statistical analysis plan and violations of clinical trial blinding procedures. By midday, analysts began assessing the impact of these findings on Capricor’s wider development pipeline, noting that the agency’s concerns specifically target the foundational integrity of the trial data rather than merely secondary efficacy endpoints.
What could happen next
While a CRL signifies that the current application is rejected, it does not permanently bar Deramiocel from future approval. However, the path to a resubmission is narrow. Given the FDA’s assessment that the data is not subject to post hoc remediation, Capricor Therapeutics will likely be required to conduct new, controlled trials to prove the therapy’s efficacy and safety to the agency’s standards. Investors should monitor upcoming disclosures from Capricor regarding their capital reserves and whether they possess the funding to initiate a new Phase 3 study, as the company’s ability to remain solvent through a multi-year trial process remains the primary risk factor.
SOURCES — THE RECORD
- FDA Issues Complete Response Letter for DeramiocelPARENT PROJECT MUSCULAR DYSTROPHY · parentprojectmd.org
- Capricor Therapeutics Regulatory UpdateFDA / PPMD · vertexaisearch.cloud.google.com
- Duchenne Cardiomyopathy Research OversightPARENT PROJECT MUSCULAR DYSTROPHY · parentprojectmd.org





